News Releases

Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company’s Commercial Capabilities in Preparation for a

Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 2, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier

Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier

Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, such

Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development   Operations SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 3, 2026-- Spruce Biosciences, Inc.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 28, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the

Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 8, 2026-- Spruce Biosciences, Inc.